Island Pharmaceuticals (ASX:ILA) Debt-to-Equity : 0.80 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Debt-to-Equity?

Island Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.51 Mil. Island Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Island Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$0.64 Mil. Island Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.80.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Island Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ASX:ILA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.42 Max: 0.8
Current: 0.8

During the past 3 years, the highest Debt-to-Equity Ratio of Island Pharmaceuticals was 0.80. The lowest was 0.04. And the median was 0.42.

ASX:ILA's Debt-to-Equity is ranked worse than
83.05% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs ASX:ILA: 0.80

Island Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Island Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Debt-to-Equity Chart

Island Pharmaceuticals Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Equity

Island Pharmaceuticals Semi-Annual Data
	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			-	-	0.04	-	0.80

Competitive Comparison of Island Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Island Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Island Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Debt-to-Equity falls into.

Island Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Island Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.785
	=	0.00

Island Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.508	+	0)	/	0.638
	=	0.80

Island Pharmaceuticals (ASX:ILA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Island Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals (ASX:ILA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its lead asset ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases.

Island Pharmaceuticals (ASX:ILA) Headlines

No Headlines